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Background/aim: To evaluate the clinical and histopathological effects of fetal brain tissue derived mesenchymal stem cells (FBTMSC)
and fibrin glue (FG) on the facial nerve (FN) regeneration in rats with traumatic FN injury.
Materials and methods: Twenty-eight Sprague Dawley rats were included in the study and divided into 4 groups. Traumatic FN injury
(FP) was created by a surgical clamp compression to the main trunk of left FN in all groups. In the control group (group 1) no treatment
was applied, in group 2 (FBTMSC group) 2 × 106 FBTMSC was injected, in group 3 (FG group) only FG was applied, in group 4
(FBTMSC and FG groups) both FBTMSC and FG were applied to the injured section of the nerve. The FN functions were evaluated
clinically, immediately after the procedure and at 3rd, 5th, and 8th weeks postoperatively. The FNs of all subjects were excised after the
8th week; then the rats were sacrificed. The presence of stem cells in the injured zone was assessed using bromo-deoxyuridine (BrdU),
and apoptosis was determined by the TUNEL method.
Results: After the damage, total FP was observed in all subjects. Statistically significant functional improvement was observed in group
4 compared to all other groups (P < 0.005). TUNEL-positive cell count was statistically significantly higher in the control group than
the other groups (P < 0.001). TUNEL-positive cell count was statistically significantly lower in group 4 than the other groups. The
proportion of BrdU-stained cells in group 4 (5%) was higher than group 2 (2%).
Conclusion: Clinically and histopathologically FBTMSC applied with FG may play a promising role as a regenerative treatment in
posttraumatic FP.
Key words: Facial nerve, facial nerve palsy, trauma, stem cell implantation, fetal brain tissue derived mesenchymal stem cells

1. Introduction
The facial nerve (FN), with its multiple functions, is one
of the most sensitive cranial nerves against traumas due
to its complex and unique anatomical structure [1]. The
paralysis of the facial nerve (FP) causes worsening of the
quality of life and consequent social and psychological
disorders, owing to loss of many functions and aesthetic
appearance in face. Therefore, full recovery of FP is very
important.
The most common cause is Bell’s palsy. Traumatic FP
that develops due to blunt and penetrating traumas, and

iatrogenic causes is the second most common. Infections
and tumors are rare causes of FP [1]. Recovery may not
be satisfactory after complete axonal injury of FN [2]. In
addition, Wallerian degeneration after axonal damage
starts to develop within days[3].
Although many methods have been used so far in
the rehabilitation of FP, there have been no excellent
effective results in functional recovery [4,5]. These
methods include observation with or without medical
treatment, physical therapy, surgical FN decompression,
neurorrhaphy, autologous nerve grafting, and nerve
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transposition [6,7]. Although the most successful surgical
procedures are neurorrhaphy and autologous nerve
grafting, these procedures have some limitations including
limited donor nerves, nonaesthetic scarring, infection,
pain, long surgical times, and inadequate regeneration
[2]. If sufficient regeneration does not develop, facial
reanimation techniques such as muscle transpositions
and static suspension procedures are alternative solutions.
However, despite all these techniques, the healing process
may result in sequelae [8]. New treatment modalities are
still being developed to prevent these results and improve
the quality of life of patients.
Stem cell transplantation is a very successful treatment
modality using tissue engineering in many different
diseases. The last 2 decades of studies have shown the
positive effects of various stem cell therapies related to nerve
regeneration, in both the central and peripheral nervous
system [2,9,10]. It has been shown that the stem cell is
differentiated into Schwann cell phenotype and accelerates
axonal regeneration and provides better remyelination
[11,12]. It has also been shown that; stem cells increase
growth factor secretion in peripheral nerve damage and
thus augment regeneration with antiinflammatory action,
and replace damaged Schwann cells and motor neurons
[2,9,13].
There are studies using adult, embryo and fetal stem
cells for the regeneration of nerve damage. Many subtypes
of these stem cells such as bone marrow, mesenchymal,
and neural stem cells have been used for regeneration in
peripheral nerve damage [2,9,13,14]. In previous years,
animal studies were carried out using many kind of stem
cells in the FP that reported good results [15–22]. There is
no research in the literature about the effects of fetal brain
tissue-oriented mesenchymal stem cells (FBTMSC) on
facial nerve damage.
It has been shown that some biodegradable materials
and pharmacological agents may contribute to nerve
regeneration. These materials provide a protein rich
environment, increase stem cell adhesion and promote
axonal growth [2,23]. For this purpose, many different
materials and pharmacological agents have been used
[9,15,17–20,22,24,25]. Fibrin glue (FG) application alone
has been shown in the studies that accelerate nerve
regeneration [26,27].
In this study, we aimed to investigate the effects of
local administration of rat FBTMSC together with FG, on
functional and histological recovery of crush injury of FP
in rats.
2. Materials and methods
2.1. Study population and design
A total of 28 adult female Sprague Dawley rats weighing
between 250 and 300 g were included in the study. Subjects
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were hosted in the Experimental Animals Laboratory,
during the study, within an environment of 12 h light/12 h
dark, temperature of 24–26 ° C with 60%–70% moisture,
and fed ad libitum. The study was carried out with the
approval of the Animal Ethics Board of our hospital
(2015/2024).
The animals were anesthetized and then left facial
nerves were identified surgically in all groups. The left
facial nerves of all animals were damaged by a direct
surgical mosquito compression. Fifteen minutes after
the iatrogenic injury to the nerve, different treatment
modalities were applied for each group:
1. Control group: no treatment was applied (group 1,
n = 7).
2. FBTMSC group: 2 × 106 FBTMSC was injected into
the damaged zone (group 2, n = 7).
3. FG group: only fibrin glue (FG) (Tisseel VH; Baxter,
Vienna, Austria) was applied over the damaged zone
(group 3, n = 7).
4. FBTMSC and FG groups: the damaged part was first
injected 2 × 106 FBTOMSC and then covered with FG
(group 4, n = 7).
Facial functions of the subjects were evaluated
immediately after recovery from anesthesia, and then
3, 5 and 8 weeks after surgery. The damaged section
of the FN of all subjects was excised at the 8th week for
histopathological examinations (TUNEL) and evaluation
of stem cell implantation (BrdU). All subjects were then
sacrificed.
2.2. Detection, identification, and marking of
mesenchymal stem cells from fetal brain tissue
The brain tissue was removed from the fetus taken from
an 18-days pregnant rat under deep anesthesia with
xylazine and ketamine in sterile conditions. It was divided
into 1 cm3 pieces and seeded in culture dishes with the
explant method. Passage of the mesenchymal stem cell
cultures in 5% CO2 incubator (20% fetal bovine serum
(Lonza, Verviers, Belgium), 2% L-glutamine (Lonza),
1% penicillin, streptomycin, amphotericin (Biological
Industries, Beit-Haemek, Israel) and 77% Dulbecco’s
modified eagle medium (DMEM-LG, Lonza) was done
when the cells filled 80% of the culture dishes by changing
the medium once every 3 days. After the second passage,
the cells were identified in flow cytometry (FACSAria III,
San Jose, CA,USA) according to CD11b/c (BD, USA),
CD45 (BD, USA), CD90 (BD, USA), CD44 (BD, USA)
surface markers (Figure 1). Cells after the second passage
were then differentiated into adipocytes, osteocytes, and
chondrocytes by the following differentiation methods.
MSCs obtained from the second passage were placed
in the culture dishes after the passage and when they
covered more than 40% of the container and they were
taken to the adipocyte medium [adipocyte differential
basal medium and supplement (Gibco, Gaithersburg,
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Figure 1. Characterization of FBTMSCs in flow cytometer according to their surface markers
(FACSAria III, USA) with: CD11b/c (–), CD45 (–), CD90 (+), CD44 (+).

MD,USA)]. Replacing the medium on a 3-day basis,
dyeing was performed according to the principle that
lipid droplets appear red within the cell with Oil Red
(Diagnostics BioSystem, Pleasanton, CA, USA) at the end
of the 3rd week (Figure 2a).
For differentiation of osteocytes, the osteocyte
differentiation basal medium and supplement (Gibco)
were used. MSCs from the second passage were planted in
the culture dishes after the passage and after covering 40%
of the dishes, the medium was changed with osteocyte

medium every 3 days. At the end of the 3rd week, staining
was performed according to the principle of black staining
of calcium deposits with the Von Kossa staining system
(Diagnostics BioSystem) (Figure 2b).
MSCs from the second passage were re-passaged, and
when they covered 40% of the culture dishes, chondrocyte
medium (chondrocyte differential basal medium and
supplementation (Gibco) was added for chondrocyte
differentiation every 3 days. At the end of the 3rd week,
Alcian blue (Diagnostics BioSystem) was used to dye
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Figure 2. Histochemical staining of adipocyte, osteocyte and chondrocyte transformation representing the transformation of
three different germ-layer structures for the characterization of FBTMSCs: a: demonstration of adipocyte differentiation (Oil Red,
Diagnostics BioSystem) with the appearance of lipid droplets in the cell to appear red(Leica D50, 10 × 40). b: demonstration of
osteocyte differentiation (Von Kossa, Diagnostic BioSystem) with staining of calcium deposits according to the principle of black
staining (Leica D50, 10 × 10). c: demonstration of chondrocyte differentiation (Alica blue, Diagnostics BioSystem) and hyaluronic
acid staining based on blue/purple staining principle (Leica D50, 10 × 20).

hyaluronic acid based on the blue/purple staining principle
(Figure 2c).
Before transplantation, the number and viability of
the cells were evaluated with the Countess automated
cell counter (Invitrogen, USA) and the cells stained with
10 μL/mL BrdU (bromo-deoxyuridine, 1 mM BrdU in 1
× Dulbecco’s phosphate buffered saline, BD Pharmingen,
US) that were prepared at a concentration of 2 × 106 cells/
mL. The solution was carefully added and incubated for
2 h. Cells labeled with BrdU were given in a 1cc insulin
injector [1cc Dulbecco 1s PBS + 2 × 106 cells (FBTMSC)]
to be used in the experiment.
The 4-µm (micrometer) sections were obtained from
formalin-fixed, paraffin-embedded tissues and then
the tissues were treated with sequential alcohol and
deparaffinized with xylen. Immunohistochemical staining
was performed with BrdU detection kit (BD-Pharmingen),
after treatment with 3% H2O2 followed by washing with
PBS. The ratio of BrdU(+) was obtained by counting 100
cells, 3 times in 20 (20 X 10) areas, from the specimens
that included facial nerve segments from the rats treated
with FBTMSC.
2.3. Surgical procedure
After anesthesia with xylazine hydrochloride (3 mg/
kg) and ketamine hydrochloride (100 mg/kg), the left
infraauricular region was shaved and sterilized to create
FN damage. A horizontal incision extending from the
postauricular region to the mandibular side was made and
the skin and subcutaneous tissues were passed, and the
parotid gland was reached. The parotid gland was excised
and the FN main trunk was identified at the anterior
aspect of the posterior digastric muscle. The nerve damage
was created just proximal to the nerve trifurcation using
microforceps compression for 30 s. The damage was
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repeated for another 30 s. The same researcher performed
the compression to all subjects. Stem cells were injected
into the damaged area, and FG was applied to the same
area as well. The surgical area was then properly closed.
The subjects were anesthetized 8 weeks after the initial
procedure as mentioned above. The FN was reexposed with
the same incision, the damaged area was found and the
injured nerve segment was resected. Then, FN specimen
was prepared and fixated in 4% paraformaldehyde
solution. The rats were then sacrificed.
2.4. Physical examination evaluation method
Immediately after the initial surgical procedure and at
the 3rd, 5th, and 8th weeks postoperatively, the FN motor
function examinations of all rats were done according
to the standardized scale with observation of vibrissae
movement and the standardized scale with observation of
blink reflex and eye closure [28].
2.5. Histochemical method
The FN tissue specimens obtained from all subjects were
first fixated in 10% formaldehyde solution for at least 72
h for light microscopic examination. After fixation, tissue
samples were placed in cassettes and washed under stream
for 24 h. Tissues were removed from the increased alcohol
series (50%, 70%, 80%, 90%, 100%) for removal of water.
Afterwards, the tissues were passed through xylene to be
transparent and then embedded in paraffin. Four-µm thick
sections were cut from prepared paraffin blocks.
2.6. TUNEL assay
The TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end labeling) method was used to determine
apoptosis developed by DNA fragmentation. Millipore
Apoptag Plus peroxidase in situ apoptosis detection kit
(Millipore, Cat no: S7101, Darmstadt, Germany) was used
for this method. Cross sections were incubated at 61 °C.
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After deparaffinization, the tissues were incubated with
20 μg/mL proteinase K (Millipore, Catalogue no. 21627,
Germany) at 37 °C for 25 min. Endogenous peroxidase
activity was blocked in tissues with 3% hydrogen peroxide
for 15 min. The cross sections were incubated with the
equilibration buffer for 5 min at room temperature.
Sections were incubated with working strength TdT
enzyme solution in a humid environment at 37 °C for
60 min. Then, tissues were incubated for 10 min in stop/
wash buffer solution and then incubated with antidigoxin
peroxidase solution for 30 min in a humid environment.
Subsequent staining with diaminobenzidine was used to
identify TUNEL-positive cells. Mayer’s hematoxylin was
used as a background stain. Cross sections were evaluated
under a light microscope using a computer-supported
imaging system to take photographs using the Leica Q
Vin 3 program. TUNEL-positive cells were counted at
400 × magnification in random areas containing the nerve
bundles in the tissue sections of the subjects.
2.7. Statistical analysis
The normal distribution of the variables was analyzed
graphically and by the Shapiro–Wilk test. Descriptive
data were presented with mean ± standard deviation and
median (25th–75th percentiles) values. The Kruskal–
Wallis nonparametric analysis of variance was used to
compare the skewed data that did not provide parametric

test assumptions. Within time differences were analyzed
by the Friedman test. In order to determine the different
group, a Connover–Dunn pairwise comparison test was
performed. Statistical analysis and calculations were
performed using IBM SPSS Statistics Version 22.0 (IBM
Corp., Armonk, NY, USA) program. In statistical decisions
P ≤ 0.05 was accepted as an indicator of significant
difference.
3. Results
3.1. Physical examination evaluation
Left total FP was observed in all rats immediately after the
procedure, and at the 3rd, 5th, and 8th weeks blink reflex, eye
closure and vibrissae position were compared. According to
intra-group comparisons; in all groups, the 5th and 8th week
values were found to be statistically significantly better than
the postoperative results. According to the comparisons
between groups; in all weeks, blink reflex and eye closure
degree in group 4 were found to be statistically better than
the other groups (Table 1).
The vibrissae monitoring score was found to be the
highest in group 4 at the 3rd week evaluation, and there
was a difference between group 4 and group 3 only at the
5th week. The results of group 1 and group 3 at the 8th
week were significantly lower than that of group 2 and
group 4. When compared to the immediate postinjury

Table 1. Statistical evaluation of blink reflex and eye closure results.
Groups
Control (group 1)

After surgery

3rd week

5th week

8th week

median 25th–75th pctl median 25th–75th pctl median 25th–75th pctl median 25th–75th pctl

P2

1.00

1.00–1.00

1.00

1.00–2.00

3.00

2.00–3.00

3.00

1.00–4.00

0.012*

FBTMSC (group 2) 1.00

1.00–1.00

2.00

1.00–3.00

3.00

2.00–3.00

4.00

3.00–4.00

<0.001*

FG (group 3)
FBTMSC and FG
(group 4)
P1

1.00

1.00–1.00

2.00

1.00–2.00

2.00

2.00–3.00

2.00

2.00–4.00

0.001*

1.00

1.00–1.00

3.00

3.00–3.00

4.00

3.00–4.00

5.00

4.00–5.00

<0.001*

1.000

0.002

0.037

0.003

P1; Kruskal–Wallis test, P2; Friedman test.
Table 2. Statistical evaluation of Vibrissae clinical observation.
After surgery
Median 25th–75th pctl
Control (group 1)
1.00
1.00–1.00
FBTMSC (group 2) 1.00
1.00–1.00
FG (group 3)
1.00
1.00–1.00
FBTMSC and FG
1.00
1.00–1.00
(group 4)

Groups

P1

1.000

3rd week
Median 25th–75th pctl
2.00
2.00–2.00
2.00
2.00–2.00
2.00
1.00–2.00

5th week
Median 25th–75th pctl
3.00
3.00–3.00
3.00
3.00–3.00
2.00
2.00–3.00

8th week
Median 25th–75th pctl
3.00
3.00–3.00
4.00
4.00–4.00
3.00
2.00–3.00

3.00

3.00

5.00

0.001

3.00–4.00

0.014

3.00–4.00

4.00–5.00

P2
<0.001*
<0.001*
0.001*
<0.001*

<0.001

P1; Kruskal–Wallis test, P2; Friedman test.
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evaluations; in all groups 5th and 8th week results were
better (Table 2).
3.2. TUNEL
TUNEL-positive cell values in all groups and were obtained
as 31.42 ± 10.84; 12.06 ± 5.44; 8.28 ± 3.04 and 5.33 ± 2.44
respectively. The TUNEL-positive cell count of group 1 was
significantly higher than the treatment groups (Figures 3
and 4a). The number of TUNEL-positive cells decreased
in all treatment groups compared to the control group (P <
0.001) (Figure 3). The difference between group 2 (Figure
4b) and group 4 was found to be statistically significant
(P < 0.001). Similarly, there was a statistically difference
between group 3 (Figure 4c) and group 4 (Figure 4d) (P
< 0.041). However, there was no significant difference
between the groups 2 and 3 (P = 0.167) (Figures 3 and 4).
3.3. BrdU staining results
BrdU staining results of BrdU detection kit (BDPharmingen) showed the percentage of BrdU(+) (Prepared
by BrdU and obtained by counting 100 cells 3 times in
20 X 10) in 20 (20 X 10) area of the facial nerve traction
obtained from rats. No staining was observed in group 1
(Figure 5a) whereas 2% was found in group 2 (Figure 5b),
as well as 5% in group 4 (Figure 5c).
4. Discussion
Although peripheral nerves are capable of self-healing
after traumas; regeneration and functional improvements
after severe damages may not be satisfactory [18]. Any new
method or treatment modality to accelerate regeneration
and provide full functional recovery in traumatic

nerve paralysis, is invaluable. Recent advances in tissue
engineering and stem cell transplantations with different
cell differentiation capacities give a new perspective to this
field. It has been shown in several studies that, stem cells,
can accelerate the regeneration of the damaged nerves by
producing adhesion molecules, neurotrophins and growth
factors or by replacing Schwann cells or even by replacing
the neurons [2,9,13,14]. It is reported that Schwann cell
plays a major role in peripheral nerve regeneration and
can be used in nerve injuries since the differentiation of
the stem cell to the Schwann cell was determined [11].
Mesenchymal stem/stromal cells have been shown to
have antiinflammatory effects; by expressing IL-1 receptor
antagonists and also have negative feedback effects on
proinflammatory cytokines [29]. This is another feature
that will explain the positive effects of stem cell therapy
on nerve regeneration. Similarly, another study has shown
that mesenchymal stem cell accelerates axonal growth by
neurotrophic and proangiogenic activity [30].
The effectiveness of stem cell technology in different
peripheral neural damages has been shown in studies. In
one study, local mesenchymal stem cell injection in the
damaged area has been shown to accelerate recovery in
recurrent laryngeal nerve injury [31]. In their study, Lerner
et al. found no significant difference with the control group
in terms of functional recovery in the recurrent laryngeal
nerve injury with intravenous mesenchymal stem cell
therapy; but the control group of this study also gained
normal functions in less time than expected [32]. In
experimental animal models, stem cells have been shown
to provide nerve regeneration in sciatic nerve injury

Figure 3. Quantitative summary of TUNEL-positive cell count for all groups.
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Figure 4. Photomicrographs representing TUNEL-positive staining on the nerve tissues of all the groups (DAB, hematoxylin) a: the
highest number of positive cells in the control group; b: reduced number of positive cells in the FBTMSC group; c: reduced number
of positive cells in the FG group; d: minimum number of positive cells in the FBTMSC and FG groups.

Figure 5. Demonstration of BrR1-labeled MSCs in tissues by immunohistochemical staining (brown nucleated cells). a: control group/
group 1 [BrdU (–)]. b: FBTMSC group/group 2 [BrdU (+)]. c: FBTMSC and FG groups/group 4 [BrdU (+)] Leica DM 4000 (Wetzlar,
Germany).
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through antiinflammatory effects, growth factor secretion,
Schwann cell or motor neuron differentiation [13].
Matthes et al. showed that intravenous transplantation of
mesenchymal stromal cells to rats with sciatic nerve injury
contributed to peripheral nerve regeneration clinically and
histologically with footprint analysis [33]. In this study, 21
days after intravenous transplantation of mesenchymal
stromal cells, histological examination of the damaged
nerve showed that these cells were present in the area
where nerve damage was present and functional recovery
was superior as well. The study of Yamamoto et al. is based
on the potential neurotrophic and neuro-differentiated
feature of mesenchymal stem cells. Dental pulp stem cell
effect was compared with autograft and collagen scaffolds
on the damaged sciatic nerve in rats and regeneration
in the stem cell transected group was superior to other
groups [34]. Considering the high likelihood of sequelae
in severe traumatic FP and medical treatment for sequelae
may not be sufficient, it is mandatory to develop a new
treatment alternative. Unlike other skeletal muscles, the
atrophy of the mimic muscles develops many years after
nerve paralysis, but even without atrophy, FP causes a high
level of psychological stress. There are some experimental
stem cell studies in the literature for facial nerve injury.
In posttraumatic FP in humans, facial decompression
was performed and a positive result was obtained in a
study, in which bone marrow mononuclear stem cells were
also applied to the damaged area [7]. Wang et al. compared
the bone marrow mesenchymal stem cell application with
Schwann-like mesenchymal stem cells in rabbits with
facial nerve damage, and concluded that the Schwann-like
mesenchymal stem cell gave more positive results in axon
regeneration and remyelination [15]. Batioglu–Karaaltin
et al. showed the efficacy of human olfactory stem cell in
nerve regeneration in facial nerve damage they formed in
rats [16]. Zhang et al. in a model of facial nerve damage they
created in rabbits, used neural stem cells supplemented
with hyaluronic acid, collagen and neurotrophin-3 and
determined that this might be an alternative modality
in the management of the treatment of peripheral nerve
defects [17]. Cho et al. in a model of facial nerve injury
that they formed in guinea pigs, used neural mesenchymal
stem cells together with platelet-rich plasma. In this study,
the authors concluded that only stem cell administration
is not effective but it promotes nerve regeneration of the
stem cell used with platelet-rich plasma [18]. Ma et al. used
neural stem cells supplemented with fibroblast growth
factor on collagen scaffold in facial nerve injury and
observed significant neural proliferation and functional
recovery [19]. Sasaki et al. applied poly-DL-lactide-coglycole tubes carrying dental pulp cells on damaged rat
facial nerves and observed remyelination and regeneration
in nerves [20]. Satar et al. in their study, created damage
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to facial nerve branches in rats and applied mesenchymal
stem cells [21]. They stated that mesenchymal stem cell
had positive effects on histopathological damage on
facial nerve branches. Shi et al. applied neural stem cells
composed of glia-derived neurotrophic factor, exfoliated
polyglycolic acid on damaged rat facial nerves and
observed increased physiological, histochemical, and
histopathological regeneration [22].
Strategically, the first important point in stem cell
therapy is to define which cells can be used in what
kind of pathologies. The second important point is the
preparation of such cells in a manner which will not harm
the patient, and the third important point is the proper
placement of these cells. There are various opinions about
the superiority of local or systemic administrations in stem
cell transplantation [15,35]. Akiyama et al. investigated the
effects of intravenous bone marrow cells on demyelinated
spinal cord [36]. However, the desired effect in this study
was less than expected probably due to the systemic
distribution of the given cells. In the studies, stem cells
for peripheral nerve injuries have been generally applied
locally. For this reason, in our study local injection was
performed because of our expectation that it will have a
more local effect, which was also thought to be augmented
with FG.
FG, with its fibrin-like effect that plays a role in
coagulation, has been shown to be as effective as
microsurgery on peripheral nerve injury [26]. In an in
vivo rat model, it has been shown that regeneration is
accelerated by FG in sciatic nerve injury [27]. In another
study, growth factor added to FG was shown to increase the
expression of p75NTR in peripheral nerve regeneration in
Schwann cells [28]. It was stated that FG formed a 3-D
matrix for nerve regeneration and its application was easy
especially with stem cells. In our study, FG was used to
provide stabilization of stem cell in the damaged area, and
this 3-D environment was considered to be suitable for
neurogenesis [37]. According to the results of our study,
both functional and TUNEL outcomes were better in the
FG group compared to the control group. The group 4, in
which FG was administered with stem cells, yielded the
best functional and TUNEL results compared to the other
groups.
In the TUNEL test, the highest rate of apoptosis
occurred in control group. The second highest rate was
observed in group 2. It was considered to be relevant to the
fact that FBTMSCs were destroyed very quickly due to high
cytotoxic cytokine release in the damaged area. The low
incidence of apoptotic cells and the high rate of BrdU(+)
in the stem cells group where FBTMSCs were given with
fibrin glue, could be interpreted as FG protected the stem
cells from the cytokine release and contributed to tissue
reparation by keeping these cells in the damaged area.

BAYIR et al. / Turk J Med Sci
In our study, we determined that FBTMSC applied
with FG provided the most appropriate microenvironment
for nerve regeneration. Our clinical observation results
showed that the group reaching the highest functional
results was group 4. Although, only stem cell and FG
groups also had better results compared with the control
group, the expected clinical and histopathological effects
were not as fast. At the end of the 8th week, significant
clinical improvement was observed in all groups compared
to immediate results after the surgical injury. This result
could be attributed to the fact that the damage was a crush
type rather than a full nerve cut.
In conclusion, in this study, it has been shown both
clinically and histopathologically that FBTMSC combined
with FG local application might play a promising role as a
form of adjunctive regenerative therapy in traumatic facial
paralysis. In this context, it is thought that these results will
provide a significant contribution to the literature, as well

as satisfactory results for patients when they enter clinical
practice. However, these results need to be confirmed in a
larger population and by human studies. We think that our
study will provide a basis for human stem cell studies to
provide functional clinical improvement in traumatic FP.
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